Abivax SA (ABVX)
| Market Cap | 914.82M |
| Revenue (ttm) | 5.13M |
| Net Income (ttm) | -164.16M |
| Shares Out | 62.92M |
| EPS (ttm) | -3.69 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 30,239 |
| Open | 14.88 |
| Previous Close | 14.92 |
| Day's Range | 14.32 - 15.10 |
| 52-Week Range | 8.00 - 17.02 |
| Beta | 1.37 |
| Analysts | Buy |
| Price Target | 18.00 (+23.8%) |
| Earnings Date | Apr 2, 2024 |
About ABVX
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France. [Read more]
Financial Performance
In 2023, Abivax's revenue was 4.62 million, an increase of 0.83% compared to the previous year's 4.58 million. Losses were -147.74 million, 143.2% more than in 2022.
Financial numbers in EUR Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for ABVX stock is "Buy." The 12-month stock price forecast is $18.0, which is an increase of 23.80% from the latest price.
News
Abivax reports 2023 financial results and operational update
Abivax reports 2023 financial results and operational update Raised EUR 500M in 2023, including a EUR 130M capital increase, two structured debt financing transactions aggregating EUR 150M and EUR 223...
Abivax Announces Presentation of Four Abstracts for Obefazimod in Ulcerative Colitis and Sponsorship of Scientific Symposium at The 19th Congress of European Crohn's and Colitis Organization (ECCO)
PARIS, FRANCE / ACCESSWIRE / February 13, 2024 / Abivax SA (Euronext Paris:ABVX))(NASDAQ:ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics th...
Citi Appointed as Depositary Bank for Abivax SA's ADR Program
LONDON--(BUSINESS WIRE)--Citi, acting through Citibank N.A., has been appointed by Abivax SA (“Abivax”), to act as depositary bank for its initial public offering (the “IPO”) of Abivax's American Depo...
Abivax Announces Closing of its Initial Public Offering on the Nasdaq Global Market
PARIS, FRANCE / ACCESSWIRE / October 24, 2023 / Abivax SA (Euronext Paris:FR0012333284 - ABVX) (" Abivax " or the " Company "), a clinical-stage biotechnology company focused on developing therapeutic...
Abivax Announces Trading Resumption of its Ordinary Shares on Euronext Paris
PARIS, FRANCE / ACCESSWIRE / October 20, 2023 / Abivax SA (Euronext Paris:FR0012333284 - ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics th...
Abivax Announces the Pricing of its Initial Public Offering on the Nasdaq Global Market
PARIS, FRANCE / ACCESSWIRE / October 20, 2023 / Abivax SA (Euronext Paris:FR0012333284:ABVX) (" Abivax " or the " Company "), a clinical-stage biotechnology company focused on developing therapeutics ...
Abivax Announces Temporary Trading Halt of its Ordinary Shares on Euronext Paris
PARIS, FRANCE / ACCESSWIRE / October 20, 2023 / Abivax SA (Euronext Paris: FR0012333284 - ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics t...
Abivax increases size of Nasdaq uplisting deal
Abivax S.A. ABVX, -2.53% has increased the size of its global offering to 20.33 million shares from 18.68 million shares as part of its uplisting to the Nasdaq under the ticker symbol “ABVX” from Euro...
Abivax Announces the Filing of an Amended Registration Statement, Including an Estimated Initial Public Offering Price Range
PARIS, FRANCE / ACCESSWIRE / October 18, 2023 / Abivax SA (Euronext Paris: FR0012333284 - ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics t...
Abivax Announces the Start of the Roadshow for its Proposed Global Offering and Proposed Nasdaq Listing
PARIS, FRANCE / ACCESSWIRE / October 16, 2023 / Abivax SA (Euronext Paris: FR0012333284 - ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics t...